CrushSCI.com
160.5Average days
124Median days
47Fastest days
351Longest days
362025 publications

Paper Review Records

All Paper Review Records

12 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

52 days

Pharmacological enhancement of O-GlcNAcylation attenuates lung ischemia-reperfusion injury

Authors
Yang Jin; Yu Fu; Nan Zhang; Xuemei Jiang; Jiameng Gao; Zhiyuan Zhang; Xiaotong Huang; Maojun Zhou; Chang Chen; Zongmei WenShow moreShow less
Affiliations
Department of Anesthesiology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China; Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, ChinaShow moreShow less
Source PDF DOI Publisher page
287 days

Belumosudil improves experimental pulmonary fibrosis via the ROCK2/Smad3/CTGF pathway

Authors
Dexin Kong; Guanghua Zhang; Zhonghong Jiang; Wanglin JiangShow moreShow less
Affiliations
School of Pharmacy, Shandong Medical and Pharmaceutical University, Yantai, 264003, PR China; Yantai Center for Food and Drug Control, Yantai, 264011, PR China; West China School of Pharmacy, Sichuan University, Chengdu, 640041, PR ChinaShow moreShow less
Source PDF DOI Publisher page
57 days

Efficacy and safety of magnesium glycinate as add on therapy in hypomagnesemic asthma and chronic obstructive pulmonary disease patients: A randomised controlled study assessing inflammatory biomarkers

Authors
Maneesh Kumar Maddirevula; Muhasaparur G. Rajanandh; Boman WesleyShow moreShow less
Affiliations
Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalapattu, Tamil Nadu, 603203, India; Department of Pharmacy Practice, Mahathi College of Pharmacy, Madanapalle, Andhra Pradesh, 517319, India; Department of Pulmonary Medicine, Arogyavarm Medical Center, Madanapalle, Andhra Pradesh, 517319, IndiaShow moreShow less
Source PDF DOI Publisher page
113 days

m6A reader IGF2BP2 mediates airway remodeling by stabilizing Dixdc1 in asthma pathogenesis

Authors
Xiao-Mang Li; Bi-Wen Mo; Yan Gao; Yun-Xiang Chen; Bo Xiao; Yue Gu; Miao-Miao Liang; Hui-Min LiShow moreShow less
Affiliations
Guilin Medical University, Guilin, 541004, Guangxi, China; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, 541001, Guangxi, China; Respiratory Disease Laboratory, The First Affiliated Hospital of Guilin Medical University, Guilin, 541004, Guangxi, ChinaShow moreShow less
Source PDF DOI Publisher page
135 days

Real-life application of the optical beta-adrenergic sweat test for people with cystic fibrosis

Authors
Karina Kleinfelder; Anca Manuela Hristodor; Giorgio Centin; Antonella Casiraghi; Paola Minghetti; Emily Pintani; Marina Bertini; Claudio Sorio; Paola MelottiShow moreShow less
Affiliations
Department of Medicine, Division of General Pathology, Cystic Fibrosis Laboratory “D. Lissandrini”, University of Verona, Verona, 37134, Italy; Cystic Fibrosis Centre, Azienda Ospedaliera Universitaria Integrata Verona, Verona, 37126, Italy; Department of Pharmaceutical Sciences, Università degli Studi di Milano, via G. Colombo 71, Milan, 20133, ItalyShow moreShow less
Source PDF DOI Publisher page
47 days

Effects of anumigilimab, an anti–G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers

Authors
Jens M. Hohlfeld; Meike Müller; Philipp Badorrek; Laurent B. Nicolas; Oliver Vit; William G. Darby; Judith Field; Michael LarbigShow moreShow less
Affiliations
Division of Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Nikolai-Fuchs-Str. 1, Hannover, 30625, Germany; Department of Respiratory Medicine and Infectious Disease, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover, 30625, Germany; Member of the German Center for Lung Research (DZL), BREATH, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover, 30625, Germany; Clinical Pharmacology and Pharmacometrics, CSL Behring AG, Wankdorfstrasse 10, Bern, 3014, Switzerland; Clinical Development, CSL Behring AG, Wankdorfstrasse 10, Bern, 3014, Switzerland; CSL Innovation, 30 Flemington, Parkville, 3010, AustraliaShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does PULMONARY PHARMACOLOGY & THERAPEUTICS take to review a manuscript?

As of 2026-11-19, CrushSCI has 12 complete review records for PULMONARY PHARMACOLOGY & THERAPEUTICS. The fastest paper went from submission to acceptance in 47 days (Effects of anumigilimab, an anti–G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers, received 2026-05-19, accepted 2026-07-05); the slowest took 351 days. The average is 160.5 days and the median is 124 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.